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1. Introduction 
Asthma is defined as a chronic inflammatory disorder of the lower airways resulting in an 
obstruction of airflow, which may be completely or partially reversed with or without 
specific therapy. The inflammation is an interaction between various cells and cytokines. 
Asthmatic patients have recurrent or persistent bronchospasm, which causes symptoms e.g. 
wheezing, breathlessness, chest tightness, and cough, particularly at night or after exercise.  
Chronic airway inflammation causes bronchial hyperresponsiveness (BHR), which is 
defined as the inherent tendency of the airways to narrow in response to various stimuli (eg, 
environmental allergens and irritants).1  
2. Epidemiology 
The prevalence of childhood asthma is 10 times higher in developed countries (UK, US, 
Australia and New Zealand) than in developing countries. Low income population in urban 
areas have higher prevalence rate than other groups (ISAAC).2-6 
Asthma in children accounts for more school absences and more hospitalizations than any 
other chronic illness and is the most common diagnosis at admission.7 
300 million individuals worldwide have asthma. Prevalence of asthma is increasing, 
especially in children. WHO has estimated that 15 million disability-adjusted life-years are 
lost and 250,000 asthma deaths are reported worldwide.8 
3. Pathophysiology  
The interplay between environment and genetic factors lead to airway inflammation, which 
result in functional and structural changes in the airways in the form of bronchospasm, 
mucosal edema, and mucus plugs, which increases resistance to airflow and decreases 
expiratory flow rates. Although over-distention helps maintain airway patency, and 
improves expiratory flow; it also alters pulmonary mechanics and increases the work of 
breathing, resulting ultimately in alveolar hypoventilation.9  
Changes in airflow resistance, uneven distribution of air, and alterations in circulation 
(mainly vasoconstriction from increased intra-alveolar pressure due to hyperinflation) lead 
to ventilation-perfusion mismatch. 10-13 
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Patients with acute asthma exacerbations in the early stages, have hypoxemia in the absence 
of carbon dioxide retention, as increases in alveolar ventilation prevents hypercarbia. 14 
If obstruction continues and ventilation-perfusion mismatch worsens, carbon dioxide 
retention and respiratory alkalosis occur. Later, the increased work of breathing, increased 
oxygen consumption, and increased cardiac output lead to metabolic acidosis. Respiratory 
failure leads to respiratory acidosis. 15-16 
4. Inflammation of the airways  
The inflammatory process in the airways causes increased BHR, which leads to bronchospasm 
and typical symptoms of wheezing, shortness of breath, and coughing after exposure to 
allergens, environmental irritants, viruses such as RSV, Rhinovirus a.o., cold air, or exercise. 17 
Lymphocytes play a central role in the pathogenesis of asthma. Airway inflammation may 
represent a mis-balance between two "opposing" populations of T helper (Th) lymphocytes. 
Two types of Th lymphocytes have been characterized: Th1 and Th2. Th1 cells produce 
interleukin (IL)-2 and interferon-a (IFN-a), which are critical in cellular defense mechanisms 
in response to infection. Th2, in contrast, generates a family of cytokines (interleukin-4 [IL-
4], IL-5, ILL6, IL-9, and IL-13) that can mediate allergic inflammation.18-22 
 
Cytokines play a key role in orchestrating the chronic inflammation of asthma and other obstructive airways 
disease recruiting, activating, and promoting the survival of multiple inflammatory cells in the respiratory tract. 
Cytokines are classified into lymphokines (cytokines that are secreted by T cells and regulate immune responses), 
proinflammatory cytokines (cytokines that amplify and perpetuate the inflammatory process), growth factors 
(cytokines that promote cell survival and result in structural changes in the airways), chemokines (cytokines that 
negatively modulate the inflammatory response).23 
Epithelial cells in the airways play an important role in orchestrating the inflammation of asthma through the 
release of multiple cytokines. Th2 cells orchestrate the inflammatory response in asthma through the release of 
IL-4 and IL-13 (which stimulate B cells to synthesize IgE), IL-5 (which is necessary for eosinophilic 
inflammation), and IL-9 (which stimulates mast cell proliferation). Mast celles are thus orchestrated by several 
interacting cytokines and play an important role in asthma through the release of the bronchoconstrictor 
mediator histamine, cysteinyl-leukotrienes (Cys-LTs), and PGD2) 
Bronchial biopsies from asthmatics show infiltration with eosinophils, activated mast cells, and T cells that are 
predominantly Th2 cells. There are characteristic structural changes, with collagen deposition under the epithelium 
(also described as basement membrane thickening) and increased airway smooth muscle as a result of hyperplasia 
hypertrophy. There is also an increase in the number of blood vessels angiogenesis) as well as mucus hyperplasia.24 
In patients with asthma, there is an increase in the number of CD4+ Th cells in the airways, which are predominantly 
of the Th2 subtype. Th2 cells are characterized by secretion of IL-4, IL-5, IL-9, and IL-13. The transcription factor 
GATA-binding protein 3(GATA3) is crucial for the differentiation of uncommitted naïve T cells into Th2 cells and 
regulates the secretion of Th2 cytokines. There is an increase in the number of GATA3+ T cells in the airways of 
stable asthmatic subjects. Nuclear factor of activated Tcells (NFAT) is a T-cell-specific transcription factor and 
enhances the transcriptional activation of the IL4 promoter by GATA3. Finally, IL-33, a member of the IL-1 family of 
cytokines, promotes differentiation of Th2 cells by translocating to the nucleus and regulating transcription through 
an effect on chromatin structure, but it also acts as a selective chemoattractant of Th2 cells.25 
IL-4 plays a critical role in differentiation of Th2 cells from uncommitted Th0 cells and may be important in initial 
sensitization to allergens. It is also important for isotype switching of B cells from producers of IgG to producers of 
IgE. IL-12 mimics IL-4 in inducing IgE secretion and causing structural changes in the airways but does not play a 
role in promoting Th2 cell differentiation. 
IL-5 plays a key role in inflammation mediated by eosinophils, since it is critically involved in the differentiation 
of eosinophils from bone marrow precursor cells and also prolongs eosinophils survival. Systemic and local 
administration of IL-5 to asthmatic patients results in an increase in circulating eosinophils and CD34+ 
eosinophil precursors. 
The transcription factor T-bet is crucial for the Th1 cell differentiation and secretion of the Th1-type cytokine IFN-┛. 
Consistent with the prominent role of Th2 cells in asthma, T-bet expression is reduced in T cells from the airways of 
asthmatic patients compared with airway T cells from nonasthmatic patients. 
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In recent years more focus on “the hygiene hypothesis”, which is in a simplified way, a 
cytokine imbalance resulting in a dramatic increase in asthma prevalence in Westernized 
countries. This hypothesis is based on the concept that the immune system of the newborn is 
skewed toward Th2 cytokine generation (mediators of allergic inflammation). 
Environmental stimuli such as infections activate Th1 responses and bring the Th1/Th2 
relationship to an appropriate balance.28-30 
 
 
 
 
Type 1 IFNs (IFN-┙ and IFN-┚) and type III IFNs (IFN-┣) play an important role in innate immunity against viral 
infections, but IFN-┚ and IFN-┣ show reduced expression in epithelial cells of asthmatic patients and are 
associated with increased rhinovirus replication, which may predispose these patients to viral exacerbations of 
asthma. 
IL-12 plays an important role in differentiating the activating Th1 cells and is produced by activated 
macrophages, DCs, and airway epithelial cells. IL-12 induces T cells to release IFN-┛, which regulates the 
expression of IL-12R┚2 and so maintains the differentiation of Th1 cells, whereas IL-4 suppresses IL-12R┚2 
expression and thus antagonizes Th1 cell differentiation.26 
Thymic stromal lymphopoietin. Thymic stromal lymphopoietin (TSLP) is a cytokine belonging to the IL-7 family 
that shows a marked increase in expression in airway epithelium and mast cells of asthmatic patients. TSLP is 
released from airway epithelial cells, and its synergistic interaction with IL-1┚ and TNF-┙ results in the release of 
Th2 cytokines from mast cells independently of T cells. TSLP also plays a key role in programming airway DCs 
to release the Th2 chemoattractants CCL17 and CCL2 and thus is important in recruiting Th2 cells to the airways. 
GM-CSF plays role in the differentiation and survival of neutrophils, eosinophils, and macrophages and has been 
implicated in asthma. Its receptor comprises and ┙-chain that is specific for the receptor for GM-CSF and a ┚-
chain that is also part of the receptors for IL-3 and IL-5. GM-CSF is secreted predominantly by macrophages, 
epithelial cells, and T cells in response to inflammatory stimuli. Airway epithelial cells of asthmatic patients 
strongly express GM-CSF, which may condition DCs to direct Th2 immunity and to prolong the survival of 
eosinophils.27 
Neutrophins are cytokines that play an important role in the function, proliferation, and survival of autonomic 
nerves. In sensory nerves, neutrophins increase responsiveness and expression of tachykinins. Nerve growth 
factor (NGF) may be produced by mast cells, lymphocytes, macrophages, and eosinophils as well as structural 
cells, such as epithelial cells, fibroblasts, and airwy smooth muscle cells. 
A series of epidemiological studies in Europe, Canada, and Australia showed reduced prevalence of asthma and 
allergy among farmers’ children compared to non-farmers’ children. Stable visits early in life and consumption or 
raw cow’s milk were suggested as the main factors of the farming environment conferring protection against 
atopic diseases. These results have been seen as an extension of the ‘hygiene hypothesis’, since a farm 
environment provides an enormous habitat for microorganisms. 
Pattern-recognition receptors (RPR) of the innate immune system, such as toll-like receptors (TLR) or CD14, 
recognize LPS (lipopolysaccharide), a component of the outer membrane of gram-negative bacteria, and other 
nonviable environmental compounds. Activation of PRR signaling pathways initiates regulatory mechanisms 
which in turn modulate the adaptive immune response. Interestingly, recently it has been shown that farmers’ 
children express higher levels of PRR than children from non-farming families suggesting that innate immune 
mechanisms are involved in the allergy-protective effect of the farming environment. 
For various genetic loci, i.a. the CD14 an association with the occurrence of atopic diseases have been described. 
However, studies investigating the same genetic variants in other populations often failed to reproduce the 
original results. 
Gene environment interactions have been found for several genetic polymorphisms in PRR genes. 
Several studies indicated higher gene expression of CD14,TLR 2, and TLR4 in farmers’ children compared to non-
farmers’ children. Mainly prenatal factors accounted for these differences. Expression of CD14, TLR2, TLR4 with 
the number of farm animal species the mother had contact with during pregnancy, which probably serves as 
proxy for an increasing variation in microbial exposure. Children of mothers who worked on the farm during 
pregnancy were less sensitized at school age to common inhalant and food allergens than children of unexposed 
mothers. However development of clinical symptoms of atopic disease seemed to depend on exposures that 
occurred postnatally.33 
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Evidence suggests that the prevalence of asthma is less in children who experience:  
 Less frequent use of antibiotics  
 Exposure to other children (eg, presence of older siblings and early enrollment in 
childcare)  
 Rural living  
 Certain infections (Mycobacterium tuberculosis, measles, or hepatitis A) 
On the contrary, the absence of these lifestyle events is associated with the persistence of a 
Th2 cytokine pattern (Allergy).  
The genetic background of a child, with a cytokine imbalance toward Th2, sets the stage to 
promote the production of immunoglobulin E (lgE) antibody to key environmental antigens 
(e.g., cockroaches, dust mites, cats and alternaria). Therefore, a gene-by-environment 
interaction occurs in which the susceptible host is exposed to environmental factors that are 
capable of generating IgE, and sensitization.34  
Allergic inflammation may be the result of an excessive expression of Th2 cytokines. Recent 
studies have suggested the possibility that the loss of normal immune balance arises from a 
cytokine dysregulation in which Th1 activity in asthma is diminished . 
5. Genetic factors and asthma  
Recent research studies have identified phenotypes (clusters) of genes which could 
predispose individuals to asthma. Cluster 1 patients have early-onset atopic asthma and 
preserved lung function but increased medication requirements (29% on three or more 
medications) and health care utilization. 35  
 
Genetic Factors 
Genome-wide linkage studies and case-control studies have identified 18 genomic regions and more than 100 
genes associated with allergy and asthma in 11 different populations. A recent genome-wide association study 
identified a new gene, ORMDL3, that exhibited a highly significantly association with asthma (p < 10-12) (for 
single nucleotide polymorphism rs8067378, odds ratio 1.84, 95% confidence interval 1.43-2.42) a finding that has 
now been replicated in several populations. 
Several studies identified candidate genes in a pathway that initiates type 2 helper T-cell (Th2) inflammation in 
response to epithelial damage and points to other candidate genes that may act in a pathway that down-regulates 
airway inflammation and remodeling. Our study also shows that asthma is heterogeneous: later-onset cases are 
influenced more by the MHC (major histocompatibility complex) than are childhood-onset cases. There is a 
strong and specific effect of the chromosome 17q locus on childhood-onset disease.37 
SNPs at the chromosome 17q21 locus associated with asthma are also strongly associated with variation in the 
expression of ORMDL3 and GSDMB.  
There is an association between SNPs flanking IL33 on chromosome 9 and atopic asthma. 38 
The locus chromosome at 2, implicating 1L1RL1 and IL 18R1 is also associated with asthma. The effect at this 
locus has been attributed to IL 1RL1 (encoding the receptor for interleukin) 6 and synergizes with IL 12 to induce 
the production of interferon-y and to promote Th1 responses. The expression of IL 18R1 is also concentrated 
within the respiratory epithelium.39 
SMAD3 is a transcriptional modulator activated by transforming growth factor ┚, a polypeptide that controls 
proliferation, differentiation, and other functions in many cell types, including regulatory T cells. 40  
HLA-DQ was the first identified asthma susceptibility locus. Extended haplotypes encompassing HLA-DQ and 
HLA-DR have been studied for their effects on specific allergen sensitization and on the formation of tumor 
necrosis factor and related gene products. 
Two other genes, SLC22A5 and RORA. SLC22A5 encodes a carnitine transporter and, like ORMDL3/GSDMB 
and IL18R1/IL1RL1.41 
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Cluster 2 comprises mostly older obese women with late-onset non-atopic asthma, moderate 
reductions in pulmonary function, and frequent oral corticosteroid use to manage 
exacerbations. Cluster 3 and cluster 4 patients have severe airflow obstruction with 
bronchodilator responsiveness but differ in to their ability to attain normal lung function, 
age of asthma onset, atopic status, and use of oral corticosteroids. 36 
6. Specific and non-specific triggers  
Specific immune-response to triggers entails 2 types of bronchoconstrictor responses to 
allergens: early and late. 42 
Early asthmatic responses occur via IgE-induced mediator release from mast cells within 
minutes of exposure and last for 20-30 minutes. 43-45 
 
 
 
Late asthmatic responses occur 4-12 hours after antigen exposure and result in more severe 
symptoms that can last for hours and contribute to the duration and severity of the disease. 
Inflammatory cell infiltration and inflammatory mediators play a role in the late asthmatic 
response. Allergens can be foods, household inhalants (eg, animal allergens, molds, fungi, 
cockroach allergens, dust mites), or seasonal outdoor allergens (eg, mold spores, pollens, 
grass, trees).  
Non-specific response e.g. tobacco smoke, cold air, chemicals, perfumes, paint odors, hair 
sprays, air pollutants, and ozone can initiate BHR by inducing inflammation. 9  
Sudden changes in ambient temperature, barometric pressure, and the quality of air (eg, 
humidity, allergen and irritant content) can also induce asthma exacerbations.10 
Exercise can trigger an early asthmatic response. Different mechanisms are hypothesized to 
play a role. Heat and water loss from the airways can increase the osillolarity of the fluid 
lining the airways and result in mediator release. Cooling of the airways results in 
congestion and dilatation of bronchial vessels. During the rewarming phase after exercise, 
the changes are magnified because the ambient air breathed during recovery is warm rather 
than cool.  
Emotional factors are sometimes incriminate to trigger asthma exacerbation (stress, 
emotional upsets a.o.)  
William et al found an increase rates of sensitization to indoor and outdoor aeroallergens throughout childhood. 
He also found different aeroallergens to be prominent at different ages. For example, dogs and cats were the 
most likely sensitizers in children younger than 4, whereas dust mites and trees were the most prominent in 
older children and adolescents.46 
There was a relatively high rate of tree sensitization in the children less than 4 years of age. 
The same study found that 57.2% of the referred patients who under SPT were sensitized to at least 1 of the 
studied aeroallergens, 51.3% of patients were sensitized to at least 1 indoor aeroallergen, and 38% were 
sensitized to at least 1 outdoor aeroallergen.47-49 
Cat, dogs, and dust mites are the predominant sensitizers in younger children, whereas trees and dust mites are 
the most prevalent sensitizers in older children and adolescents. In contrast to grass and ragweed tree 
sensitization is much more common than expected in very young children.50 
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7. Gastroesophageal reflux  
The presence of acid in the distal esophagus, mediated via vagal or other neural reflexes, can 
significantly increase airway resistance and airway reactivity.  
8. Upper respiratory tract: conditions  
Inflammatory conditions of the upper airways (eg, allergic rhinitis, sinusitis, or chronic and 
persistent infections) must be treated before asthmatic symptoms can be completely 
controlled. 
9. Circadian rhythm  
Circadian variation in lung function and inflammatory mediator release in the circulation 
and airways (including parenchyma) have been demonstrated to explain nocturnal asthma. 
Other factors, such as allergen exposure and posture-related irritation of airways (eg, 
gastroesophageal reflux, sinusitis), can also play a role. In some cases, abnormalities in CNS 
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control of the respiratory drive may be present, particularly in patients with a defective 
hypoxic drive and obstructive sleep apnea. 51 
 
10. Asthma outcome  
Children with mild asthma who are asymptomatic between attacks are likely to improve 
and be symptom-free later in life.  
Children with asthma appear to have less severe symptoms as they enter adolescence, but half of 
these children continue to have asthma. Asthma has a tendency to remit during puberty, with a 
somewhat earlier remission in girls. However, compared with men, women have more BHR. 59 
Of infants who wheeze with URTls, 60% are asymptomatic by age 6 years. However, 
children who have asthma (recurrent symptoms continuing at age 6 years) have airway 
reactivity later in childhood. Some findings suggest a poor prognosis if asthma develops in 
children younger than 3 years, unless it occurs solely in association with viral infections. 60-62 
Individuals who have asthma during childhood have significantly lower forced expiratory 
volume in 1 second (FEV1), higher airway reactivity, and more persistent bronchospastic 
symptoms than those with infection-associated wheezing.  
11. Patient education  
11.1 Pediatrician and/or asthma educator should instruct 
Patient and parent on how to use medications and devices (eg, spacers, nebulizers, metered-
dose inhalers [MDls]). The patient's MOl technique should be assessed on every visit.63 
Instruction should also includes the use of medications, precautions with drug and/or 
device usage, monitoring symptoms and their severity (peak flow meter reading), and 
identifying potential adverse effects and necessary actions. 64 
It is well known that there is a circadian variation in asthma severity and exacerbation. 
Wheezing, cough and dyspnea are worse during the late night and early morning hours3. Most dyspneic 
episodes occurring nocturnally, with a 50-fold increase in the number of attacks between 4 am and 5 am 
compared with the number of attacks between 4 pm and 5 pm.4 Objective indicators of disease severity correlate 
closely with subjective dyspnea PEFR begins declining rapidly at midnight, and at 4 am is between 8% and 40% 
below its mean 24-hour value at 9 am. The PEFR then increases sharply and reaches its mean 24 hour value at 8 
am.5 Normal subjects also show circadian changes in airflow, with mild nocturnal bronchoconstriction, although 
the variation is far less pronounced than that seen in asthmatic subjects.52 
The pathophysiology of nocturnal asthma exacerbation is not completely understood and appears to be 
multifactorial. Plasma cortisol levels vary markedly, reaching a nadir at midnight and peaking at 8 am. Serum 
histamine levels peak dramatically at about 4 am, dropping to baseline levels by 8 am. Plasma cyclic 
AMP(cAMP) levels reaches a nadir at 4 am, as do the density and responsiveness of beta-adrenergic receptors 
located on circulating leukocytes. A nocturnal increase in vagal tone has been described. All of these factors 
appear to play a role in destabilizing the inflammatory environment of the airways at night. Additionally, sleep-
induced oxygen dessaturation, gastroesophageal reflux, and body temperature decline during sleep may all 
predispose to nocturnal airway hyperresponsiveness.55-53 
The circadian nature of asthma has led to the argument that nocturnal presentation of asthma is marker of more 
severe disease, warranting more aggressive therapy and lower threshold for hospitalization than for other 
asthmatic patients. Data demonstrating increased asthma mortality between midnight and 4 am, although 
limited to inpatient settings, appear to support this argument. However, some studies of asthmatic patients in the 
emergency department failed to validate this hypothesis. Several studies however demonstrate no significant 
disease severity between asthmatic patients who presented during late night/early-morning hours.58-56 
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Parents should understand that asthma is a chronic disorder with acute exacerbations; 
hence, continuity of management with active participation by the patient and/or parents 
and interaction with asthma care medical personnel is important. Adherence to treatment is 
the key to full control of symptoms including nocturnal and exercise-induced symptoms. 
Emphasize the importance of adherence to treatment.65 
Parents caregiver and teachers should expect the child to participate in recreational activities 
and sports and to attend school as usual. 66 
12. Differential diagnoses  
12.1 Problems to be considered include the following 
 Vascular ring  
 Vocal cord dysfunction  
 Tracheobronchomalacia  
 Pulmonary edema  
 Gastroesophageal Reflux  
 Bronchopulmonary Dysplasia  
 Bronchiectasis  
 Aspiration Syndromes  
 Airway Foreign Body  
 Allergic Rhinitis  
 Aspergillosis  
 Cystic Fibrosis  
 Primary Ciliary Dyskinesia 67 
13. Clinical presentation  
13.1 History is very important in asthma the clinician should confirm 
 Airflow obstruction or symptoms are at least partially reversible  
 Episodic symptoms of airflow obstruction are present  
 Alternative diagnoses are excluded  
Obtaining a good patient history is crucial when diagnosing asthma and excluding other 
causes, symptoms, aggravating factors and co-existing conditions should be asked.  
 Shortness of breath  
 Cough  
 Wheezing  
 Cough at night or with exercise 
 Chest tightness 
 Sputum production 
 Onset and duration  
 Perennial, seasonal, or both 
 Daytime or nighttime 
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 Continuous or intermittent 
 Exercise  
 Viral infections 
 Irritants (eg, smoke exposure, chemicals, vapors, dust)  
 Environmental allergens 
 Changes in weather  
 Emotions 
 Stress  
 Foods  
 Home environment (eg, carpets, pets, mold)  
 Drugs (eg, aspirin, beta blockers)  
 Rhinitis  
 Sinusitis  
 Gastroesophageal reflux disease (GERD)  
 Thyroid disease  
 
 
Vascular rings are unusual congenital anomalies that occur early in the development of 
the aortic arch and great vessels. The primary symptomatology associated with vascular 
rings relates to the structure that are encircled by the ring, chiefly the trachea, large 
airways and esophagus. 
PERINATAL AND FAMILY HISTORY POSSIBLE DIAGNOSIS  
Symptoms present from birth or perinatal 
lung problem 
Cystic fibrosis; chronic lung disease of 
prematurity; ciliary dyskinesia; developmental 
anomal 
Family history of unusual chest disease Cystic fibrosis; neuromuscular disorder 
Severe upper respiratory tract disease Defect of host defence; ciliary dyskinesia 
Symptoms and signs  
Persistent moist cough 
Cystic fibrosis; bronchiectasis; protracted 
bronchitis; recurrent aspiration; host defence 
disorder; ciliary dyskinesia 
Excessive vomiting Gastroesophageal reflux (+-aspiration) 
Dysphagia Swallowing problems (+- aspiration) 
Breathlessness with light-headedness and 
peripheral tingling 
Hyperventilation/panic attacks 
Inspiratory stridor Tracheal or laryngeal disorder 
Abnormal voice or cry Laryngeal problem 
Focal signs in chest 
Developmental anomaly; post-infective 
syndrome; bronchiectasis; tuberculosis 
Finger clubbing Cystic fibrosis; bronchiectasis 
Failure to thrive 
Cystic fibrosis; host defense disorder; 
gastroesophageal 
Other conditions 
Transient infant wheezing 
Onset in infancy; no associated atopy associated 
with parental smoking 
Inhaled foreign body  Suddent onset 
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The family history should include any history of asthma, allergy, sinusitis, rhinitis, eczema, 
or nasal polyps in close relatives, and the social history should cover factors that may 
contribute to non adherence of asthma medications, as well as any illicit drug use.68-72  
Physical findings vary with the absence or presence of an acute episode and its severity.  
A patient with mild asthma may have normal findings on physical examination. Patients 
with more severe asthma are likely to have signs of chronic respiratory distress and chronic 
hyperinflation.  
Signs of atopy or allergic rhinitis, such as conjunctival congestion and inflammation, allergic 
shiners, a transverse crease on the nose due to constant rubbing associated with allergic rhinitis, 
and pale nasal mucosa covered with transparent mucus due to allergic rhinitis, may be present. 
The anteroposterior diameter of the chest may be increased because of hyperinflation. 
Hyperinflation may also cause an abdominal breathing pattern.  
Lung examination may reveal prolonged expiratory phase, expiratory wheezing, coarse 
crackles, or unequal breath sounds.  
Clubbing of the fingers is not a usual feature of asthma and indicates a need for more 
extensive evaluation and work-up to exclude other conditions, such as cystic fibrosis. 73-77  
A child with an acute episode may reveal different findings in mild, moderately severe, and 
severe episodes and in status asthmaticus with imminent respiratory arrest.  
13.2 Mild episode asthma reveals 
 Accessory muscles of respiration are not used  
 Increased respiratory rate  
Differential Diagnosis of Asthma in Children 5 years and younger 
Infections: 
 Recurrent Respiratory tract infections 
 Chronic rhino-sinusitis 
 Tuberculosis. 
Congenital problems: 
 Tracheomalacia 
 Cystic Fibrosis 
 Bronchopulmonary dysplasia 
 Congenital malformation causing narrowing of the intratoracic airways. 
 Primary ciliary dyskinesia syndrome 
 Immune deficiency 
 Congenital heart disease 
Mechanical Problems 
 Foreign body aspiration 
 Gastroesophageal reflux 
Adopted from GINA Guide 2011
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 The heart rate is less than 100 beats per minute  
 Auscultation of chest reveals moderate wheezing, which is often end expiratory  
 Pulsus paradoxus is not present  
 Oxyhemoglobin saturation with room air is greater than 95%  
13.3 Moderately severe asthma include the following 
 Increased respiratory rate  
 Accessory muscles of respiration typically are used  
 Suprasternal retractions are present  
 The heart rate is 100-120 beats per minute  
 Loud expiratory wheezing can be heard  
 Pulsus paradoxus may be present (10-20 mm Hg)  
 Oxyhemoglobin saturation with room air is 91-95%  
13.4 Severe asthma include the following: 
 The respiratory rate is often greater than 30 breaths per minute  
 Accessory muscles of respiration are usually used  
 Suprasternal retractions are commonly present  
 The heart rate is greater than 120 beats per minute  
 Loud biphasic (expiratory and inspiratory) wheezing can be heard  
 Pulsus paradoxus is often present (20-40 mm Hg)  
 Oxyhemoglobin saturation with room air is less than 91 %.  
13.5 Status asthmaticus may include the following 
 Paradoxical thoracoabaominal movement  
 Wheezing may be absent (in patients with the most severe airway obstruction)  
 Severe hypoxemia may manifest as bradycardia  
 Pulsus paradoxus may disappear; this finding suggests respiratory muscle fatigue  
14. Workup  
Spirometry is indicated in children >6 years, as younger children < 6 years are unable to 
perform spirometry, unless modern techniques such as measurement of airway resistance 
using oscillometry is applied.  
In a typical case, an obstructive defect is present in the form of normal forced vital capacity 
(FVC), reduced forced expiratory volume in 1 second (FEV1), and reduced forced expiratory 
flow more than 25-75% of the FVC (FEF 25-75). The flow-volume loop can be concave. 
Documentation of reversibility of airway obstruction after bronchodilator therapy is 
essential to the definition of asthma. FEF 25-75 is a sensitive indicator of obstruction and 
may be the only abnormality in a child with mild disease.  
In an outpatient or office setting, measurement of the peak flow rate by using a peak flow 
meter can provide useful information about obstruction in the large airways.  
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15. Plethysmography  
Patients with chronic persistent asthma may have hyperinflation, as evidenced by an 
increased total lung capacity (TLC) at plethysmography. Increased residual volume (RV) 
and functional residual capacity (FRC) with normal TLC suggests air trapping. Airway 
resistance is increased when significant obstruction is present.  
16. Bronchial provocation tests  
Bronchial provocation tests may be performed to diagnose bronchial hyper-responsiveness 
(BHR). These tests are performed in specialized laboratories by specially trained personnel 
 
Daytime 
symptoms 
between 
exacerbations 
Night-time 
symptoms 
between 
exacerbations 
Exacerbations 
PEF or 
FEV1* 
PEF 
variability** 
Infrequent 
intermittent 
Nil Nil 
Brief 
Mild  
Occur less 
than every 4-
6 weeks 
More 
than 80% 
predicted 
Less than 
20% 
Frequent 
intermittent 
Nil Nil 
More than 2 
per month 
At least 
80% 
predicted 
Less than 
20% 
Mild 
persistent 
More than 
once per 
week but not 
every day 
More than 
twice per 
month but 
not every 
week 
May affect 
activity and 
sleep 
At least 
80% 
predicted 
20%-30% 
Moderate 
persistent 
Daily 
More than 
once per 
week 
At least twice 
per week 
Restricts 
activity or 
affects sleep 
60%-80% 
predicted 
More than 
30% 
Severe 
presistent 
Continual Frequent 
Frequent 
restricts 
activity 
60% 
predicted 
or less 
More than 
30% 
ADAPTED GINA 2008 
An individual’s asthma pattern (infrequent intermittent, frequent intermittent, mild 
persistent, moderate persistent or severe persistent) is determined by the level of the 
table that corresponds to the most severe feature present. Other features associated with 
that pattern need not be present. 
*Predicted values are based on age, sex, and height. 
*Difference between morning and evening values. 
FEV1: Forced expiratory volume in 1 second: PEF: Peak expiratory flow. 
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to document airway hyper-responsiveness to substances (eg, methacholine, histamine). 
Increasing doses of provocation agents are given, and FEV1 is measured. The endpoint is a 
20% decrease in FEV1 (PD20). 90-92 
17. Exercise challenge  
In a patient with a history of exercise-induced symptoms (eg, cough, wheeze, chest tightness 
or pain), the diagnosis of asthma can be confirmed with the exercise challenge. In children 
>6 years old, the procedure involves baseline spirometry followed by exercise on a treadmill 
or bicycle to a heart rate greater than 60% of the predicted maximum, with monitoring of the 
electrocardiogram and oxyhemoglobin saturation.93  
Spirographic findings and the peak expiratory flow (PEF) rate (PEFR) are determined 
immediately after the exercise period and at 3 minutes, 5 minutes, 10 minutes, 15 minutes, 
and 20 minutes after the first measurement. The maximal decrease in lung function is 
calculated by using the lowest post-exercise and highest pre -exercise values. The 
reversibility of airway obstruction can be assessed by administering aerosolized 
bronchodilators.94-95  
18. Chest X-ray  
Chest X-ray is indicated in the initial work-up of asthmatic patients. Typical findings are 
hyperinflation and increased bronchial markings, a chest radiograph may reveal evidence of 
parenchymal disease, atelectasis, pneumonia, congenital anomaly, or a foreign body.  
In a patient with an acute asthmatic episode that responds poorly to therapy, a chest 
radiograph helps in the diagnosis of complications such as pneumothorax or 
pneumomediastinum.  
19. Paranasal sinus and CT scanning  
Consider sinus radiography and CT scanning to rule out sinusitis, co-existing with allergic 
rhinitis and asthma.  
20. Blood testing  
CBC, Eosinophil counts, total IgE and RAST may be useful when allergic factors are 
suspected.  
21. Skin prick test  
Allergy testing can be used to identify allergic factors that may significantly contribute to 
the asthma. Once identified, environmental factors (eg, dust mites, cockroaches, molds, 
animal dander) and outdoor factors (eg, pollen, grass, trees, molds) may be controlled or 
avoided to reduce asthmatic symptoms.  
Allergens for skin testing are selected on the basis of suspected or known allergens 
identified from a detailed environmental history. Antihistamines can suppress the skin test 
results and should be discontinued for an appropriate period (according to the particular 
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agent's duration of action) before allergy testing. Topical or systemic corticosteroids do not 
affect the skin reaction.  
22. Fraction of Exhaled Nitric Oxide testing  
Measuring the fraction of exhaled nitric oxide (FeNO) has proved useful as a non-invasive 
marker of airway inflammation, in order to guide adjustment of the dose of inhaled 
corticosteroids. 96-98 
23. Histologic findings  
Asthma is an inflammatory disease characterized by inflammatory cells, vascular 
congestion, increased vascular permeability, increased tissue volume, and the presence of an 
exudate.  
Eosinophilic infiltration, a universal finding, is considered a major marker of the 
inflammatory activity of the disease. 
Histologic evaluations of the airways in a typical patient reveal infiltration with 
inflammatory cells, narrowing of airway lumina, bronchial and bronchiolar epithelial 
denudation, and mucus plugs. 99-104 
Additionally, a patient with severe asthma may have a markedly thickened basement 
membrane and airway remodeling in the form of subepithelial fibrosis and smooth muscle 
hypertrophy or hyperplasia.  
24. Management  
24.1 Goal for therapy  
 Control asthma by reducing impairment through prevention of chronic and 
troublesome symptoms (eg, coughing or breathlessness in the daytime, in the night, or 
after exertion)  
 Maintain near-normal pulmonary function  
 Maintain normal activity levels (including exercise and other physical activity and 
attendance at work or school)  
 Reduce the need for a short-acting beta2-agonist (SABA) for quick relief of symptoms 
(not including prevention of exercise-induced bronchospasm)  
 Satisfy patients' and families' expectations for asthma care105  
Reduction in risk can be achieved by preventing recurrent exacerbations of asthma and 
minimizing the need for emergency room visits and hospitalizations, and preventing 
progressive loss of lung growth and function providing optimal pharmacotherapy with 
minimal or no adverse effects is important.  
24.2 Pharmacologic treatment  
Pharmacologic management includes the use of agents for control and agents for relief. 
Control agents include inhaled corticosteroids, inhaled cromolyn or nedocromil, long acting 
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bronchodilators, theophylline, leukotriene modifiers, and more recent strategies such as the 
use of anti-immunoglobulin E (lgE) antibodies (omalizumab). Relief medications include 
short-acting bronchodilators, systemic corticosteroids, and ipratropium. 106-107 
For all but the most severely affected patients, the ultimate goal is to prevent symptoms, 
minimize morbidity from acute episodes, and prevent functional and psychological 
morbidity to provide a healthy (or near healthy) lifestyle appropriate to the age of child. 108 
A stepwise approach to pharmacologic therapy is recommended to gain and maintain 
control of asthma in both the impairment and risk domains. The type, amount, and 
scheduling of medication is dictated by asthma severity (for initiating therapy) and the level 
of asthma control (for adjusting therapy). Step-down therapy is essential to identify the 
minimum medication necessary to maintain control. See table below.  
For pharmacotherapy, children with asthma are divided into 3 groups based on age: 0-4 y, 
5-11 y, 12 Y and older. 109 
For all patients, quick-relief medications include rapid-acting beta2-agonists as needed for 
symptoms. The intensity of treatment depends on the severity of symptoms. If rapid acting 
beta2-agonists are used more than 2 days a week for symptom relief (not including use of 
rapid-acting beta2-agonists for prevention of exercise induce symptoms), stepping up 
treatment may be considered. See the stepwise approach to asthma medications in Table 1, 
below.  
 
 
Intermittent Asthma Persistent Asthma: Daily Medication 
Age Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 
< 5 y 
Rapid-
acting 
beta2-
agonist prn 
Low-dose inhaled 
corticosteroid 
(ICS) 
Medium-dose ICS 
Medium-dose ICS 
plus either long-
acting beta2-
agonist (LABA) or 
montelukast 
High-dose ICS 
plus either LABA 
or montelukast 
High-dose ICS plus 
either LABA or 
montelukast; Oral 
systemic 
corticosteroid 
Alternate regimen: 
cromolyn or 
montelukast 
5-11 y 
Rapid-
acting 
beta2-
agonist prn 
Low-dose ICS 
Either low-dose 
ICS plus either 
LABA, LTRA, or 
theophylline OR 
Medium-dose 
Medium-dose ICS 
plus LABA 
High-dose ICS 
plus LABA 
High-dose ICS plus 
LABA plus oral 
systemic 
corticosteroid 
Alternate regimen: 
cromolyn, 
leukotriene 
receptor 
antagonist (LTRA), 
or theophylline 
Alternate 
regimen: 
medium-dose ICS 
plus either LTRA 
or theophylline 
Alternate 
regimen: high-
dose ICS plus 
either LABA or 
theophylline 
Alternate regimen: 
high-dose ICS plus 
LRTA or 
theophylline plus 
systemic 
corticosteroid 
12 y or 
older 
Rapid-
acting 
beta2-
agonist as 
needed 
Low-dose ICS 
Low-dose ICS 
plus LABA OR 
Medium-dose ICS 
Medium-dose ICS 
plus LABA High-dose ICS 
plus LABA (and 
consider 
omalizumab for 
patients with 
allergies) 
High-dose ICS plus 
either LABA plus 
oral corticosteroid 
(and consider 
omalizumab for 
patients with 
allergies) 
Alternate regimen: 
cromolyn, LTRA, 
or theophylline 
Alternate 
regimen: low-
dose ICS plus 
either LTRA, 
theophylline, or 
zileuton 
Alternate 
regimen: 
medium-dose ICS 
plus either LTRA, 
theophylline, or 
zileuton 
Table 1. Stepwise Approach to Asthma Medications 
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In the Salmeterol Multicenter Asthma Research Trial (SMART), salmeterol use in asthma 
patients, particularly African Americans, was associated with a small but significantly 
increased risk of serious asthma-related events. This trial was a large, double-blind, 
randomized, placebo-controlled, safety trial in which salmeterol 42 mcg twice daily or 
placebo was added to usual asthma therapy for 28 weeks. 110   
The study was halted following interim analysis of 26,355 participants because patients 
exposed to salmeterol (n = 13,176) were found to experience a higher rate of fatal asthma 
events compared with individuals receiving placebo (n = 13,179); the rates were 0.1 % and 
0.02%, respectively. This resulted in an estimated 8 excess deaths per 10,000 patients treated 
with salmeterol. 111 
In the post-hoc subgroup analysis, the relative risks of asthma-related deaths were similar 
among whites and blacks, although the corresponding estimated excess deaths per 10,000 
patients exposed to salmeterol were higher among blacks than whites.  
A meta-analysis by Salpeter et al found that LABAs increased the risk for asthma related 
intubations and deaths by 2-fold, even when used in a controlled fashion with concomitant 
inhaled corticosteroids. However, the absolute number of adverse events remained small. 
The large pooled trial included 36,588 patients, most of them adults. 112 
The US Food and Drug Administration (FDA) has reviewed the data and the issues and has 
determined that the benefits of LABAs in improving asthma symptoms outweigh the 
potential risks when LABAs are used appropriately with an asthma controller medication in 
patients who need the addition of LABAs. The FDA recommends the following measures 
for improving the safe use of these drugs :  
 LABAs should be used long-term only in patients whose asthma cannot be adequately 
controlled on inhaled steroids 113 
 LABAs should be used for the shortest duration of time required to achieve control of 
asthma symptoms and discontinued, if possible, once asthma control is achieved; 
patients should then be switched to an asthma controller medication  
 Pediatric and adolescent patients who require the addition of a LABA to an inhaled 
corticosteroid should use a combination product containing both an inhaled 
corticosteroid and a LABA to ensure compliance with both medications  
Concerns about the safety of long-acting beta2-agonists and resultant drug safety 
communications create a question as to the course of treatment if asthma is not controlled by 
inhaled corticosteroidsY4] A study by Lemanske et al addressed this question and 
concluded that addition of long-acting beta2-agonist was more likely to provide the best 
response than either inhaled corticosteroids or leukotriene-receptor antagonists. Asthma 
therapy should be regularly monitored and adjusted accordingly.  
A systematic review of 18 placebo-controlled clinical trials evaluating monotherapy with 
inhaled corticosteroids supports their safety and efficacy in children with asthma. In 
addition, the data provide new evidence linking inhaled corticosteroids use in children with 
asthma to improved asthma control. A recent study to assess the effectiveness of an inhaled 
corticosteroid used as rescue treatment recommends that children with mild persistent 
asthma should not be treated with rescue albuterol alone and the most effective treatment to 
prevent exacerbations is daily inhaled corticosteroids. This study suggests that inhaled 
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corticosteroids as rescue medication with albuterol might be an effective step down strategy, 
for children as it is more effective at reducing exacerbations than is use of rescue albuterol 
alone. A recent Cochrane review concluded that more research is needed to assess the 
effectiveness of increased inhaled corticosteroid doses at the onset of asthma exacerbation]  
In children, long-term use of high-dose steroids (systemic or inhaled) may lead to adverse 
effects, including growth failure. Recent data from the Childhood Asthma Management 
Program (CAMP) study and results of the long-term use of inhaled steroids (budesonide) 
suggest that the long-term use of inhaled steroids has no sustained adverse effect on growth 
in children. 114-116  
 
 
 
A review by Rodrigo et al looked at 8 studies of omalizumab in children with moderateeto-
severe asthma and elevated IgE levels. Children treated with omalizumab were more 
significantly able to reduce their use of rescue inhalers and their inhaled and/or oral steroid 
dose than patients in the placebo group. Although no significant differences in pulmonary 
function were observed, patients receiving omalizumab had fewer exacerbations than the 
Low Daily Doses of Inhaled Glucocorticosteroids 
for Children 5 years and younger 
Drug Low Daily Dose (┤g) 
Beclomethasone dipropianate 100 
Budesonide MDI+spacer 
Budesonide nebulized 
200 
500 
Fluticasone propionate 100 
GINA Guidelines 
Omalizumab is a recombinant humanized IgG1 monoclonal anti-IgE antibody that binds to the IgE molecule 
at the same epitope on the Fc region that binds to FcεRL, Omalizumab binds to circulating IgE regardless of 
allergen specificity, forming small, biologically inert IgE-anti-IgE complexes without activating the 
complement cascade. An 89 to 99 percent reduction in free serum IgE (i.e., IgE not bound to Omalizumab) 
occurs soon after the administration of omalizumab and low levels persist throughout treatment with 
appropriate doses. Proof-of-concept studies have shown that Omalizumab reduces both early-and late –phase 
asthmatic responses after allergen inhalation challenge, has a marked effect on late-phase as compared with 
early-phase skin responses, decreases eosinophil numbers in sputum and submucosal bronchial specimens 
and also down-regulates FcεRI on basophils, mast cells, and dendritic cells. A reduction in the expression of 
FcεRI on basophils and mast cells decreases the binding of circulating IgE, thus, preventing the release of 
inflammatory mediators. A reduction in the expression of FcεRI on dendritic cells may decrease allergen 
processing. 
Several randomized, double-blind clinical trials compared omalizumab, administered subcutaneously, with 
placebo. 
These trials demonstrated a clinical benefit from Omalizumab, although the specific findings varied. Three of 
the trials evaluated patients with moderate-t0-severe persistent asthma (requiring doses of inhaled 
bleclomethasone, or its equivalent, ranging from 168-1200 μg per day). Two of these tree trials included 
adolescents and adults, and one was a study of children 6-12 years of age. Treatment with Omalizumab as 
compared with placebo was associated with significantly fewer exacerbations of asthma per patient, and a 
significantly lower percentage of patients had an exacerbation, the dose of inhaled corticosteroids required to 
control symptoms was significantly less among patients treated with Omalizumab than among those who 
received placebo. 
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children receiving placebo. These studies lasted a year or less and did not reveal any 
significant adverse effects of the omalizumab.  
 
 
A randomized trial of omalizumab for asthma in inner-city children showed improved 
asthma control, elimination of seasonal peaks in asthmatic exacerbations, and reduced need 
for other medications for asthma control.  
Clinical Use 
The role of Omalizumab in the management of asthma has not yet been precisely defined. 
Patients with persistent asthma (defined as asthma with symptoms that occur more than two days 
a week or nocturnal symptoms that occur more than twice a month) have several treatment 
options in addition to the use of inhaled β-adrenergic agonist. These include environmental 
control (i.e., the elimination or minimization of exposure to aeroallergens), pharmacologic 
control (i.e., the use of inhaled corticosteroids, leukotriene modifiers, or both), and possibly, 
immunologic control (i.e., immunotherapy for relevant antigens). In addition, evaluation for 
coexisting conditions such as allergic rhinitis, sinusitis, and gastroesophageal reflux disease may 
prove beneficial. 
 
Patients who are particularly likely to benefit from the use of Omalizumab include those with 
evidence of sensitization to perennial aeroallergens who require high doses of inhaled 
corticosteroids that have a potential for adverse side effects, those with frequent exacerbations of 
asthma associated with unstable disease and possibly, those with severe symptoms related in part 
to poor adherence to daily medication. Analysis of pooled data from published clinical trials 
have indicated that patients who had a response to Omalizumab had a ration of observed to 
expected forced expiratory volume in one second (FEV1) of less than 65 percent, were taking 
doses of inhaled corticosteroids equivalent to more than 800 μg of beclomethasone dipropionate 
per day, and had at least one visit to the emergency department in the past year. Patients 
requiring daily oral corticosteroids to control their stamina may be less likely to have response to 
Omalizumab. 
 
A total serum IgE level should be measured in all patients who are being considered for 
treatment with Omalizumab, because the dose of Omalizumab is determined on the basis of the 
IgE level and body weight. The recommended dose is 0.016 mg per kilogram of body weight per 
international unit of IgE every four weeks, administered subcutaneously at either two-week or 
four-week intervals. This dose is based on the estimated amount of drug that is required to 
reduce circulating free IgE levels to less than 10 IU per milliliter. 
 
Monitoring of total serum IgE levels during the course of therapy with Omalizumab is not 
indicated, because these levels will be elevated as a result of the presence of circulating IgE-anti-
IgE complexes. No other laboratory tests seems to be necessary, since there have been no 
clinically significant laboratory abnormalities noted during treatment. 
 
Cost 
Omalizumab is considerably more expensive than conventional asthma therapy, with an average 
of approximately $12,000 per year. This compares with approximate cosets per year of $1,289 
for montelukast, $2,160 for the combination of fluticasone dipropionate and salmeterol, $680 for 
extended-release theophylline. 
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25. Delivery devices and best route of administration  
In pediatric asthma, inhaled treatment is the cornerstone of asthma management. Inhaler 
devices currently used to deliver inhaled corticosteroids (ICSs) fall into the following 4 
categories:64  
 Pressurized metered dose inhaler (pMDI) - Propellant used to dispense steroid when 
canister is pressed manually  
 Dry powder inhaler (DPI) - Does not require hand-breath coordination to operate  
 Breath-actuated pMDI - Propellant used to dispense steroid when patient inhales  
 Nebulized solution devices  
Go to Use of Metered Dose Inhalers, Spacers, and Nebulizers for complete information on 
this topic.  
In pediatric patients, the inhaler device must be chosen on the basis of age, cost, safety, 
convenience, and efficacy of drug delivery 
Based on current research, the preferred device for children younger than 4 years is a pMDI 
with a valved holding chamber and age-appropriate mask. Children aged 4-6 years should 
use a pMDI plus a valved holding chamber. Lastly, children older than 6 years can use 
either a pMDl, a DPI, or a breath-actuated pMDI. For all 3 groups, a nebulizer with a valved 
holding chamber (and mask in children younger than 4 y) is recommended as alternate 
therapy.  
Valved holding chambers are important. The addition of a valved holding chamber can 
increase the amount of drug reaching the lungs to 20%. The use of a valved holding 
chamber helps reduce the amount of drug particles deposited in the oropharynx, thereby 
helping to reduce systemic and local effects from oral and gastrointestinal absorption.  
A Cochrane review on the use of valved holding chambers versus nebulizers for inhaled 
steroids found no evidence that nebulizers are better than valved holding chamber. 
Nebulizers are expensive, inconvenient to use, require longer time for administration, 
require maintenance, and have been shown to have imprecise dosing.  
Newer devices such as…. have been associated with a greater efficacy (as evidenced by…). 
For MDls, chlorofluorocarbon (CFC) propellants (implicated in ozone depletion) have been 
phased out in favor of the hydrofluoroalkane-134a (HFA) propellant. Surprisingly, the HFA 
component is more environmentally friendly and has proven to be more effective, due to its 
smaller aerosol particle size, which results in better drug delivery. MDls with HFA 
propellant have better deposition of drug in the small airways and greater efficacy at 
equivalent doses compared with CFC-MDls.117 
26. Long-term monitoring  
Regular follow-up visits are essential to ensure control and appropriate therapeutic 
adjustments. In general, patients should be assessed every 1-6 months. At every visit, 
adherence, environmental control, and comorbid conditions should be checked.  
If patients have good control of their asthma for at least 3 months, treatment can be stepped 
down. However, the patient should be reassessed in 2-4 weeks to make sure that control is 
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maintained with the new regimen. If patients require step 2 asthma medications or higher, 
consultation with an asthma specialist should be considered.  
27. Outpatient visits should include the following 
 Interval history of asthmatic complaints, including history of acute episodes (eg, 
severity, measures and treatment taken, response to therapy)  
 History of nocturnal symptoms  
 History of symptoms with exercise, and exercise tolerance  
 Review of medications, including use of rescue medications  
 Review of home-monitoring data (eg, symptom diary, peak flow meter readings, daily 
treatments)  
28. Patient evaluation should include the following 
 Assessment for signs of bronchospasm and complications  
 Evaluation of associated conditions (eg, allergic rhinitis)  
 Pulmonary function testing (in appropriate age group)  
Address issues of treatment adherence and avoidance of environmental triggers and 
irritants.  
Long-term asthma care pathways that incorporate the aforementioned factors can serve as 
roadmaps for ambulatory asthma care and help streamline outpatient care by different 
providers.  
In the author's asthma clinic, a member of the asthma care team sits with each patient to 
review the written asthma care plan and to write and discuss in detail a rescue plan for 
acute episodes, which includes instructions about identifying signs of an acute episode, 
using rescue medications, monitoring, and contacting the asthma care team. These items are 
reviewed at each visit.  
One study using directly observed administration of daily preventive asthma medications 
by a school nurse showed significantly improved symptoms among urban children with 
persistent asthma. 
29. Control of environmental factors and comorbid conditions  
As mentioned above, environmental exposures and irritants can play a strong role in 
symptom exacerbations. Therefore, in patients who have persistent asthma, the use of skin 
testing or in vitro testing to assess sensitivity to perennial indoor allergens is important. 
Once the offending allergens are identified, counsel patients on avoidance from these 
exposures. In addition, education to avoid tobacco smoke (both first-hand and second-hand 
exposure) is important for patients with asthma. 118 
Lastly, comorbid conditions that may affect asthma must be appropriately managed. These 
include the following:  
 Bronchopulmonary aspergillosis  
 Gastroesophageal reflux disease (GERD)  
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 Obesity  
 Obstructive sleep apnea  
 Rhinitis  
 Sinusitis  
 Depression  
 Stress  
Inactivated influenza vaccine may be helpful in those who are older than 6 months.  
30. Education  
Patient education continues to be important in all areas of medicine and is particularly 
important in asthma. Self-management education should focus on teaching patients the 
importance of recognizing their own their level of control and signs of progressively 
worsening asthma symptoms.  
Both peak flow monitoring and symptom monitoring have been shown to be equally 
effective; however, peak flow monitoring may be more helpful in cases in which patients 
have a history of difficulty in perceiving symptoms, a history of severe exacerbations, or 
moderate-to-severe asthma.  
Educational strategies should also focus on environmental control and avoidance strategies 
and medication use and adherence (eg, correct inhaler techniques and use of other devices).  
Using a variety of methods to reinforce educational messages is crucial in patient 
understanding. Providing written asthma action plans in partnership with the patient 
(making sure to review the differences between long-term control and quick-relief 
medications), education through the involvement of other members of the healthcare team 
(eg, nurses, pharmacists, physicians), and education at all points of care (eg, clinics, 
hospitals, schools) are examples of various educational tools that are available and valuable 
for good patient adherence and understanding.  
31. Status asthmaticus  
Treatment goals for acute severe asthmatic episodes (status asthmaticus) are as follows:  
 
 
 Correction of significant hypoxemia with supplemental oxygen; in severe cases, 
alveolar hypoventilation requires mechanically assisted ventilation  
Acute exacerbation of asthma induces the release of inflammatory mediators prime 
adhesion molecules in the airway epithelium and capillary endothelium, which then 
allows inflammatory cells, such as eosinophils neutrophils, and basophils, to attach to 
the epithelium and endothelium and subsequently migrate into the tissues of the 
airway. Eosinophils release eosinophilic cationic protein (ECP) and major basic protein 
(MBP). Both ECP and MBP induce deqsquamation of the airway epithelium and expose 
nerve endings. This interaction promotes further airway hyperresponsiveness in 
asthma. This inflammatory component may even occur in individuals with mild asthma 
exacerbation.  
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 Rapid reversal of airflow obstruction with repeated or continuous administration of an 
inhaled beta2-agonist; early administration of systemic corticosteroids (eg, oral 
prednisone or intravenous methylprednisolone) is suggested in children with asthma 
that fails to respond promptly and completely to inhaled beta2-agonists  
 
 
 Reduction in the likelihood of recurrence of severe airflow obstruction by intensifying 
therapy: Often, a short course of systemic corticosteroids is helpful 119-120 
Achieving these goals requires close monitoring by means of serial clinical assessment and 
measurement of lung function (in patients of appropriate ages) to quantify the severity of 
airflow obstruction and its response to treatment. Improvement in FEV1 after 30 minutes of 
treatment is significantly correlated with a broad range of indices of the severity of 
asthmatic exacerbations, and repeated measurement of airflow in the emergency 
department can help reduce unnecessary admissions.  
The use of the peak flow rate or FEV1 values, patient's history, current symptoms, and 
physical findings to guide treatment decisions is helpful in achieving the aforementioned 
goals. When using the peak expiratory flow (PEF) expressed as a percentage of the patient's 
best value, the effect of irreversible airflow obstruction should be considered. For example, 
in a patient whose best peak flow rate is 160 L/min, a decrease of 40% represents severe and 
potentially life-threatening obstruction.  
An Australian study by Vuillermin et al found that asthma severity decreased in school 
aged children when parents initiated a short course of prednisolone for acute asthma. 
Children who received parent-initiated prednisolone for episodes of asthma had lower 
daytime and nighttime asthma scores, reduced risk of health resource use, and reduced 
school absenteeism compared with children who received placebo.  
1. Yes, See British Guidelines on Management of Asthma (revised 2009). 
: second line treatment of acute asthma in children aged over 2 years. 
2. Indications for admission to intensive care or high-dependency units include patients 
requiring ventilator support and those with severe acute or life threatening asthma 
who are failing to respond to therapy, as evidenced by: 
 Deteriorating PEF 
 Persisting or worsening hypoxia 
 Hypercapnea 
 Arterial blood gas analysis showing fall in pH or rising H+ concentration 
 Exhaustion, feeble respiration 
 Drowsiness, confusion, altered conscious state 
 Respiratory arrest. 
Not all patients admitted to the Intensive Care Unit (ICU) need ventilation, but those with 
worsening hypixia or hypercapnea, drowsiness or uncousciousness and those who have had a 
respiratory arrest require intermittent positive pressure ventilation, intubation in such patients is 
very difficult and should ideally be performed by an anaesthetist or ICU consultant. 
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32. Prevention of asthma  
The goal of long-term therapy is to prevent acute exacerbations. The patient should avoid 
exposure to environmental allergens and irritants that are identified during the evaluation.  
 
33. Dietary adjustments 
When a patient has major allergies to dietary products, avoidance of particular foods may 
help. In the absence of specific food allergies, dietary changes are not necessary. Unless 
compelling evidence for a specific allergy exists, milk products do not have to be avoided.  
34. Consultations  
Any patient with high-risk asthma should be referred to a specialist. The following may 
suggest high risk:  
 History of sudden severe exacerbations  
 History of prior intubation for asthma  
 Admission to an ICU because of asthma  
 Two or more hospitalizations for asthma in the past year  
 Three or more emergency department visits for asthma in the past year  
 Hospitalization or an emergency department visit for asthma within the past month  
 Use of 2 or more canisters of inhaled short-acting beta2-agonists per month  
 Current use of systemic corticosteroids or recent withdrawal from systemic 
corticosteroids  
Referral to an asthma specialist for consultation or co-management of the patient is also 
recommended if additional education is needed to improve adherence or if the patient 
requires step 4 care or higher (step 3 care or higher for children aged 0-4 y). Consider 
referral if a patient requires step 3 care (step 2 care for children aged 0-4 y) or if additional 
testing for the role of allergy is indicated. 
The choice between a pediatric pulmonologist and an allergist may depend on local 
availability and practices. A patient with frequent ICU admissions, previous intubation, and 
a history of complicating factors or comorbidity (eg, cystic fibrosis) should be referred to a 
Recurrent acute exacerbation of asthma cause the following histoopathological change in the airways. The 
airways becomes blocked by viscous, tenacious mucus distended lung parenchyma are composed of 
eosinophils and epithelial cells. There is an increase in smooth airway muscle with hyperplasia and 
hypertrophy in the major airways. Shedding of the cilated bronchial wall cells, mainly eosinophils. Apart 
from the bronchial infiltration of eosinophils there is dilatation of the capillary blood cells. The connective 
tissue in which these vessels lie consists of strands of widely separated collagen. 
 
Numerous vasoactive agents have been found in broncoalveolar lavage of ___ with recurrent acute exacerbation 
of asthma including cell-derived mediators, such as histamine, the cysteinyl leukotriene, LTC4, LTD4 and 
LTE4, and PAF, and also neural-derived mediators, e.g. substance P(SP), neurokinin A and B (NKA, NKB), and 
calcitonin gene-related peptide (CGRP), PAF is a phospholipid that induces neutropenia, bronchocosntriction, 
and abnormal airway microvascular leakage, possibly through postcapillary venoconstriction in the 
tracheobroncial circulation. Thus microvascular leakage of plasma is an inflammatory hallmark of paramount 
relevance n asthma, generally referred to as abnormally increased vascular permeability. A substantially 
increased number of PAF receptors are reported in the lungs of asthmatic individuals. 
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pediatric pulmonologist. When allergies are thought to significantly contribute to the 
morbidity, an allergist may be helpful.  
Consider consultation with an ear, nose, and throat (ENT) specialist for help in managing 
chronic rhinosinusitis. Consider consultation with a gastroenterologist for help in excluding 
and/or treating gastroesophageal reflux.  
35. Appendix: Specific pharmacologic treatment  
35.1 Bronchodilators, Beta2-Agonists  
These agents are used to treat bronchospasm in acute asthmatic episodes, and used to 
prevent bronchospasm associated with exercise-induced asthma or nocturnal asthma. 
Recent studies have suggested that short-acting beta2-agonists may produce adverse 
outcomes (eg, decreased peak flow or increased risk of exacerbations) in patients 
homozygous for arginine (Arg/Arg) at the 16th amino acid position of beta-adrenergic 
receptor gene compared with patients homozygous for glycine (Gly-Gly). Similar findings 
are reported for long-acting beta2-agonists, such as salmeterol. 121-122 
35.2 Salbutamol sulfate (Proventil HFA, Ventolin HFA, ProAir HFA)  
This beta2-agonist is the most commonly used bronchodilator that is available in multiple 
forms (eg, solution for nebulization, MOl, PO solution, butalin, ventolin, asthalin, salamol, 
a.o.). This is most commonly used in rescue therapy for acute asthmatic symptoms. Used as 
needed. Prolonged use: may be associated with tachyphylaxis due to beta2-receptor down 
regulation and receptor hyposensitivity. 
Some MD is/are available as a breath-actuated inhalers. The ease of administration with the 
breath-actuated devices make it an attractive choice in the treatment of acute symptoms in 
younger children who otherwise cannot use an ordinary MDl. The Autohaler delivers 200 
mcg per actuation.  
Terbutalin, a partial beta-2-agonist is short-acting bronchodilator. The inhaled form of 
terbutalin starts working within 15 minutes and can last for up to 6 hours. 
This nonracemic form of beta-2-agonist (albuterol) offers a significant reduction in the 
adverse effects associated with racemic albuterol (eg, muscle tremors, tachycardia, 
hyperglycemia, hypokalemia). 
 
 
 
The noncarcemic form of albuterol Levabuterol offers a significant reduction in the 
adverse effects associated with racemic albuterol (eg, muscle tremors, tachycardia, 
hyperglycemia, Hypokalemia. 
The dose may be doubled in acute severe episodes when even a slight increase in the 
bronchodilator response may make a big difference in the management strategy (eg, in 
avoiding patient ventilation). It is available as an MDI (45 mcg per actuation) or 
solution for nebulized inhalation). 
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35.3 Xopenex 
Nonracemic form of albuterol (xopenex), levalbuterol (R isomer) is effective in smaller doses 
and is reported to have fewer adverse effects (eg, tachycardia, hyperglycemia, 
hypokalemia). The dose may be doubled in acute severe episodes when even a slight 
increase in the bronchodilator response may make a big difference in the management 
strategy (eg, in avoiding patient ventilation). It is available as an MOl (45 mcg per actuation) 
or solution for nebulized inhalation.  
35.4 Long-Acting Beta2-Agonists  
Long-acting bronchodilators (LABA) are not used for the treatment of acute bronchospasm. 
They are used for the preventive treatment of nocturnal asthma or exercise-induced 
asthmatic symptoms, for example.  
There are 2 LABA are available: salmeterol and formoterol. Both are available as 
combination products with inhaled corticosteroids. 
LABA may increase the chance of severe asthma episodes and death when those episodes 
occur. Most cases have occurred in patients with severe and/or acutely deteriorating 
asthma; they have also occurred in a few patients with less severe asthma.  
LABAs are not considered first-line medications to treat asthma. LABAs should not be used 
as isolated medications and should be added to the asthma treatment plan only if other 
medicines do not control asthma, including the use of low- or medium-dose corticosteroids. 
If used as isolated medication, LABAs should be prescribed by pulmonologist / allergist.  
35.5 Salmeterol  
This long-acting preparation of a beta2-agonist is used primarily to treat nocturnal or 
exercise-induced symptoms. It has no anti-inflammatory action and is not indicated in the 
treatment of acute bronchospastic episodes. It may be used as an adjunct to inhaled 
corticosteroids to re9uce the potential adverse effects of the steroids. The medication is 
delivered via a Diskus DPI.  
35.6 Formoterol  
Formoterol is a long-acting B2-agonist. It is marketed in dry powder inhalation, a metered-
dose inhaler, an inhalation solution and oral tablet.  
Formoterol relieves bronchospasm by relaxing the smooth muscles of the bronchioles in 
conditions associated with asthma. They are used for long-term control and prevention of 
symptoms, especially nocturnal symptoms. 
35.7 Methylxanthines  
35.7.1 Theophylline  
Theophylline is available in short-acting and long-acting formulations. Because of the need 
to monitor serum concentrations, this agent is used infrequently. The dose and frequency 
depend on the particular product selected. The actions of theophylline involve: 
www.intechopen.com
 Bronchial Asthma – Emerging Therapeutic Strategies 
 
174 
 relaxing bronchial smooth muscle 
 increasing heart muscle contractility and efficiency as a positive inotropic  
 increasing heart rate positive chronotrope 
 increasing blood pressure 
 increasing renal blood flow 
 some anti-inflammatory effects 
 central nervous system stimulatory effect mainly on medullary respiratory center.123-125 
 
 
The use of theophylline is complicated by its interaction with other drugs, chiefly cimetidine 
and phenytoin, erythromycin, ciprofloxacin and fluoroquinolones and that it has a narrow 
therapeutic index. It can cause nausea, diarrhea, tachycardia, headache, insomnia 
35.8 Inhaled corticosteroids  
Steroids are the most potent anti-inflammatory agents. Inhaled forms are topically active, 
poorly absorbed and thus less likely to cause adverse effects. They are used for long-term 
control of asthma symptoms and airway inflammation. Inhaled forms reduce the need for 
systemic corticosteroids.  
Inhaled steroids block late asthmatic response to allergens; reduce airway hyper 
responsiveness; inhibit inflammatory process e.g. cytokine production, adhesion protein 
activation, and inflammatory cell migration and activation; and reverse beta2-receptor 
downregulation and subsensitivity (in acute asthmatic episodes with LABA use). 126-127 
35.8.1 Fluticasone  
Fluticasone has extremely potent vasoconstrictive and anti-inflammatory activity. It has a 
weak hypothalamic-pituitary adrenocortical axis inhibitory potency when applied topically. 
It is available as an MDl aerosolized product (HFA) or DPI (Diskus).  
35.8.2 Budesonide  
Budesonide has extremely potent vasoconstrictive and anti-inflammatory activity. It has a 
weak hypothalamic-pituitary adrenocortical axis inhibitory potency when applied topically. 
It is available as a DPI, MDI and nebulized susp (ie, Respules).  
Parenteral methylxanthines (aminophylline, theophylline) may circumvent the dimininshed 
delivery of aerosolized ┚-agonists in acute asthma and young children thus augmenting 
submaximal bronchial smooth-muscle relaxation. Molecular mechanisms specific to theophylline 
that may be responsible for its beneficial effect include phosphodiesterase enzyme inhibition, 
adenosine receptor antagonism, enhanced catecholamine secretion, and modulation of 
transmembrane calcium fluxes in muscle cells. The influence on calcium may be respoinsble for an 
increase in respiratory muscle contractility and resistance to diaphragmatic fatigue particularly 
advantageous in asthmatics with early respiratory failure. Methylxanthines may also assume 
greater importance during ┚-receptor desensitization where the response to ┚ agonist drugs is 
attenuated but a response to aminophylline persists. Clinical trials involving submaximal 
bronchodialation have shown that the benefit from combinations of methylxanthines and ┚-
agnosits are more likely additive and synergistic.  
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35.8.3 Beclomethasone  
Beclomethasone inhibits bronchoconstriction mechanisms; causes direct smooth muscle 
relaxation, decrease the number and activity of inflammatory cells, and decreases airway 
hyperresponsiveness. It is available as MDI.  
35.8.4 Ciclesonide  
Ciclesonide is an aerosol inhaled corticosteroid indicated for maintenance treatment of 
asthma as prophylactic therapy in adolescent patients aged 12 y and older. Not indicated for 
relief of acute bronchospasm.  
Corticosteroids have wide range of effects on multiple cell types (eg, mast cells, eosinophils, 
neutrophils, macrophages, lymphocytes) and mediators (eg, histamines, eicosanoids, 
leukotrienes, cytokines) involved in inflammation.  
Maximum benefit may not be achieved for 4 wk or longer after initiation of therapy.  
After asthma stability is achieved, it is best to titrate to lowest effective dosage to reduce the 
possibility of adverse effects. For patients who do not adequately respond to the starting 
dose after 4 wk of therapy, higher doses may provide additional asthma control. It is 
available as MDI.127  
35.8.5 Mometasone furoate inhalation powder (Asmanex Twisthaler)  
Mometasone is a corticosteroid for inhalation. It is indicated for asthma as prophylactic 
therapy.  
35.9 Systemic corticosteroids  
Corticosteroids are the most potent anti-inflammatory used in asthma. Systemic 
corticosteroids (SCS) are effective in acute asthma, pulmonary function slowly improves 
beginning within 6-12 hours, SCS reduces to relapse rate and admission ranks. Several 
studies suggest duration of 3-5 days. The anti-inflammatory effects of corticosteroids are 
mediated to a major extent via TRANSREPRESSION, while many side-effects are due to 
TRANSACTIVATION. New generations of corticosteroids are being developed that 
preferentially induce TRANSREPRESSION with little or no TRANSACTIVATION.  
These agents are used for short courses (3-10 d) to gain prompt control of inadequately 
controlled acute asthmatic episodes. They are also used for long-term prevention of 
symptoms in severe persistent asthma as well as for suppression, control, and reversal of 
inflammation. Frequent and repetitive use of beta2-agonists has been associated with beta2-
receptor sub-sensitivity and down regulation; these processes are reversed with 
corticosteroids.  
Higher-dose corticosteroids have no advantage in severe asthma exacerbations, and 
intravenous administration has no advantage over oral therapy, provided that 81 transit 
time or absorption is not impaired. The usual regimen is to continue frequent multiple 
daily dosing until the FEV1 or peak expiratory flow (PEF) is 50% of the predicted or 
personal best values; then, the dose is changed to twice daily. This usually occurs within 
48 hours.  
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35.9.1 Prednisone  
An immunosuppressant for the treatment of autoimmune disorders, prednisone may 
decrease inflammation by reversing increased capillary permeability and suppressing 
polymorphonuclear neutrophil (PMN) activity.  
35.9.2 Methylprednisolone  
Methylprednisolone may decrease inflammation by reversing increased capillary 
permeability and suppressing PMN activity.  
35.10 Leukotriene modifiers  
Knowledge that leukotrienes cause bronchospasm, increased vascular permeability, 
mucosal edema, and inflammatory cell infiltration has led to the concept of modifying their 
action by using pharmacologic agents. These are either 5-lipoxygenase inhibitors or 
leukotriene-receptor antagonists. 
35.11 Leukotriene antagonists  
These are drugs that inhibit leukotrienes and thus suppress inflammation. Leukotriene 
antagonists such as montelukast, zafirlukast are used in asthma to block the actions of 
leukotrienes, either by inhibition of the cysteinyl-leukotriene type 1 receptors. (Montelukast, 
Zafirlukast)  
35.11.1 Zafirlukast  
Zapirlukast is a selective competitive inhibitor of LTD4 and LTE4 receptors.  
 
 
The leukotriene-antagonist zafirlukast (Accolate), and montelukast (Singulaire) are 
proving to be effective for long-term prevention of asthma, including exercise-induced 
asthma and aspirin (or NSAID)-induced asthma. Their anti-inflammatory actions are 
different from those of steroids. 
 
Studies suggest that montelukast, wheich comes in a chewable tablet, may be 
particularly useful for managing asthma in small children (ages two to five) with 
asthma, since they have trouble with inhaled steroids. Zafirlukast may also reduce the 
severity of cat allergies, regardless of whether or not asthma is also present. 
 
Of some concern are reports of Churg-Satrauss syncrome in a few people taking 
zafirlukast or montelukast. Churg-Strauss syndrome is very rare, but it causes blood 
vessel inflammation in the lungs and can be life threatening. Oral steroids quickly 
resolve the problem. In fact, usually the syndrome has occurred in patients who were 
tapering off steroids and changing over to the leukotrines-antagonist. Some experts 
believe that, in such cases, the steroids may simply have masked the presence of the 
disorder, which then developed when the steroid drugs were withdrawn. Symptoms 
include severe sinusitis, flu-like symptoms, rash, and numbness in the hands and feet. 
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35.11.2 Montelukast  
The last agent introduced in its class, montelukast has the advantages that it is chewable, it 
has a once-a-day dosing, and it has no significant adverse effects. 
35.11.3 Omalizumab  
Omalizumab is a recombinant, DNA-derived, humanized IgG 1K monoclonal antibody that 
selectively binds to human Immunoglobulin (IgE). Omalizumab’s cost is very high as 
compared with other drugs used for asthma, and hence is mainly prescribed for patients with 
severe persistent asthma, which can not be controlled even with high doses of corticosteroids 
like other protein drugs, omalizumab may cause anaphylaxis in 1 to 2 patients per 1000.  
35.12 Combination inhaled steroids/Long-Acting Beta2-Agonists  
These combinations may de\crease asthma exacerbations when inhaled short-acting beta2-
agonists and corticosteroids have failed. Refer to previous discussion in the LABAs section 
regarding increased risk of severe asthma episodes and death with LABAs. In a recent 
study, use of combination therapy using fluticasone propionate and salmeterol prolonged 
time to first severe asthma exacerbation.  
Budesonide is an inhaled corticosteroid that alters level of inflammation in airways by 
inhibiting multiple types of inflammatory cells and decreasing production of cytokines and 
other mediators involved in the asthmatic response. Available as MDl in 2 strengths; each 
actuation delivers formoterol 4.5 mcg with either 80 mcg or 160 mcg.  
35.12.1 Budesonide and formoterol  
Formoterol relieves bronchospasm by relaxing the smooth muscles of the bronchioles in 
conditions associated with asthma. Budesonide is an inhaled corticosteroid that alters the 
level of inflammation in airways by inhibiting multiple types of inflammatory cells and 
decreasing production of cytokines and other mediators involved in the asthmatic response. 
This combination is available as an MOl in 2 strengths; each actuation delivers formoterol 
4.5-mcg with either 80-mcg or 160-mcg of budesonide.  
35.12.2 Mometasone and formoterol  
This is a combination corticosteroid and LABA metered-dose inhaler. Mometasone elicits 
local anti-inflammatory effects in the respiratory tract with minimal systemic absorption. 
Formoterol elicits bronchial smooth muscle relaxation.  
This combination is indicated for prevention and maintenance of asthma symptoms in 
patients inadequately controlled with other asthma controller medications (eg, low-dose to 
medium-dose inhaled corticosteroids) or whose disease severity clearly warrants initiation 
of treatment with 2 maintenance therapies, including a LABA. Available in 2 strengths; each 
actuation delivers mometasone/formoterol 100 mcg/5 mcg or 200 mcg/5 mcg.  
35.12.3 Fluticasone and salmeterol  
This is a combination corticosteroid and LABA metered-dose inhaler. Fluticasone inhibits 
bronchoconstriction mechanisms, produces direct smooth muscle relaxation, and may 
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decrease number and activity of inflammatory cells, in turn decreasing airway hyper-
responsiveness. It also has vasoconstrictive activity. Salmeterol relaxes the smooth muscles 
of the bronchioles in conditions associated with bronchitis, emphysema, asthma, or 
bronchiectasis and can relieve bronchospasms. Its effect may also facilitate expectoration. 
Adverse effects are more likely to occur when administered at high or more frequent doses 
than recommended. Two delivery mechanisms are available (ie, powder for inhalation 
[Diskus], metered-dose inhaler [MDl]). Diskus is available as a combination of salmeterol 50 
mcg with fluticasone 100 mcg, 250 mcg, or 500 mcg. The MDl is available as 21 mcg 
salmeterol with fluticasone 45 mcg, 115 mcg, or 230 mcg.  
35.13 Anticholinergic drugs 
Anticholinergic drugs are group of bronchodilators that block the neurotransmitter 
acetylcholine on the muscarinic receptor on bronchial smooth muscle.  
35.13.1 Ipratropium bromide  
Chemically related to atropine, protropium has antisecretory properties and, when applied 
locally, inhibits secretions from serous and seromucous glands lining the nasal mucosa. The 
MDl delivers 17 mcg/actuation. Solution for inhalation contains 500 mcg/2.5 mL (ie, 0.02% 
solution for nebulization). 
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Source: Management of Asthma in Children aged 1-15 years (Ped. Society of New Zealand) 
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